Teva- Pharmaceutical Industries Ltd. - ADR (TEVA) Company Profile & Statistics

Teva- Pharmaceutical Industries Ltd. - ADR
TEVA
(NYSE)
N/A
13.97
-0.09 (-0.64%)
in:usd•As of: May 07, 2024 10:11 UTC -4
Open
13.94
High
14.09
Low
13.94

About Teva- Pharmaceutical Industries Ltd. - ADR

CEO

Richard D. Francis

Headquarters

124 dvora hanevi¿a street

tel aviv, l3 6944020, israel

Auditor

Kesselman & Kesselman

Employees

37,851

Share Holders

2,085

Website

www.tevapharm.com

Industry

pharmaceuticals generic

Sector

health technology

Company Overview

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.

Teva- Pharmaceutical Industries Ltd. - ADR Statistics

Valuation Measures

Market Capitalization ²	15.66B
Enterprise Value	32.27B
Enterprise Value/EBITDA (ttm)	20.35
Price to Earnings Ratio (ttm)	5.66
Price to Book (mrq)	1.93
Price to Sales (ttm)	0.99
Price to Cash (ytd)	3.97

Profitability

Gross Margin (ttm)	47.95%
Operating Margin (ttm)	17.59%
Profit Margin (ttm)	-4.04%
Return on Equity (ttm)	34.90%
Return on Invested Capital (ttm)	-2.26%
Return on Assets (ttm)	6.48%

Income Statement

Revenue (ttm)	15.85B
Revenue Per Share (ttm)	14.13
Gross Profit (ttm)	7.64B
EBITDA (ttm)³	1.59B
Net Income Avi to Common (ttm)	-559.00M
Diluted EPS (ttm)	-0.47

Share Statistics

Beta (5Y Monthly)	1.04
52-Week Change	54.19%
S&P500 52-Week Change	27.95%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	1.12B
Dividend Yield	0.00%
Float ⁴	1.11B
% Held by Insiders	0.55%
% Held by Institutions	54.05%

Balance Sheet

Total Cash (mrq)	3.23B
Total Cash Per Share (mrq)	2.88
Total Debt (mrq)	19.83B
Total Debt/Equity (mrq)	244.07%
Current Ratio (mrq)	1.02%
Quick Ratio (mrq)	0.69%
Book Value Per Share (mrq)	7.25

Cash Flow

Operating Cash Flow Per Share (ytd)	1.22
Free Cash Flow (ytd)	910.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Teva- Pharmaceutical Industries Ltd. - ADR

Trade With A Regulated Broker